A standard form of induction therapy is made up of standard dose of cytarabine (SDAraC, 100-200 mg/m2), administered by continuous infusion for 7 days and along with an administered intravenously for 3 days (referred to as 7 + 3 regimen). With standard induction regimens, remission is achieved in about 65% to 85% of younger patients but in significantly less than 50% of patients over 60 years of age.2,53 This process results in a disease-free survival of approximately 30%, with treatment-related mortality of 5% to 10%. A number of studies have been done to enhance the CR rate by use of alternative anthracyclines, incorporation of highdose AraC (HDAraC), or addition of other agencies such as etoposide, fludarabine, or cladribine. However, presently, there is no definite evidence to recommend one 7 + 3 induction regimen over another. However, these studies obviously support in conclusion that further intensification of the induction program is not connected with a heightened CR rate. In patients who don’t achieve CR following induction therapy, postinduction therapy is recommended. Postinduction ROCK inhibitor selleck therapy with standard-dose cytarabine is preferred in standard-dose cytarabine induction has been received by patients who and have in case a suitable donor are available significant residual blasts.52 In other cases, postinduction therapy may include hematopoietic stem cell transplantation. While getting an initial remission is the first faltering step in controlling the condition, it’s important that patients continue with consolidation treatment to achieve a durable remission. Patients who do not receive combination therapy will relapse within 6 to 9 months.54,55 Consolidation therapy can consist of chemotherapy or hematopoietic stem cell transplantation (HSCT), and the decision of therapy is usually dependent on patient age, comorbidities, possibility of recurrence based on cytogenetics, and whether a patient features a suitable donor for HSCT.3 The employment of HSCT is less common in patients aged over 60 years because of increased risks of transplant-related morbidity and mortality. Treatment is comprised by consolidation therapy with additional courses of intensive chemotherapy after the patient has achieved CR, often with higher doses of the exact same BMS-354825 drugs used throughout the induction period. High-dose AraC (2-3 g/m2) has become standard consolidation therapy for patients aged.